vs
Orthofix Medical Inc.（OFIX）与Xperi Inc.（XPER）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Xperi Inc.的1.9倍（$219.9M vs $116.5M），Orthofix Medical Inc.净利率更高（-1.0% vs -14.7%，领先13.7%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.8%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $1.2M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -1.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Xperi是一家美国跨国科技企业，总部位于加利福尼亚州圣何塞，专注研发消费电子与联网车载软件，以及宽带视频服务媒体平台，业务分为付费电视、消费电子、联网汽车与媒体平台四大板块，旗下拥有DTS、HD Radio、TiVo等知名品牌。
OFIX vs XPER — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$116.5M
营收增速更快
OFIX
高出6.8%
-4.8%
净利率更高
OFIX
高出13.7%
-14.7%
自由现金流更多
OFIX
多$15.7M
$1.2M
两年增速更快
OFIX
近两年复合增速
-1.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $116.5M |
| 净利润 | $-2.2M | $-17.1M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | -12.7% |
| 净利率 | -1.0% | -14.7% |
| 营收同比 | 2.0% | -4.8% |
| 净利润同比 | 92.4% | -137.0% |
| 每股收益（稀释后） | $-0.05 | $-0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXXPER
| Q4 25 | $219.9M | $116.5M | ||
| Q3 25 | $205.6M | $111.6M | ||
| Q2 25 | $203.1M | $105.9M | ||
| Q1 25 | $193.6M | $114.0M | ||
| Q4 24 | $215.7M | $122.4M | ||
| Q3 24 | $196.6M | $132.9M | ||
| Q2 24 | $198.6M | $119.6M | ||
| Q1 24 | $188.6M | $118.8M |
净利润OFIXXPER
| Q4 25 | $-2.2M | $-17.1M | ||
| Q3 25 | $-22.8M | $-6.1M | ||
| Q2 25 | $-14.1M | $-14.8M | ||
| Q1 25 | $-53.1M | $-18.4M | ||
| Q4 24 | $-29.1M | $46.2M | ||
| Q3 24 | $-27.4M | $-16.8M | ||
| Q2 24 | $-33.4M | $-30.3M | ||
| Q1 24 | $-36.0M | $-13.1M |
毛利率OFIXXPER
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXXPER
| Q4 25 | 0.2% | -12.7% | ||
| Q3 25 | -8.3% | -1.2% | ||
| Q2 25 | -7.9% | -10.5% | ||
| Q1 25 | -25.2% | -14.4% | ||
| Q4 24 | -5.3% | -11.7% | ||
| Q3 24 | -9.6% | -14.0% | ||
| Q2 24 | -12.5% | -18.3% | ||
| Q1 24 | -15.6% | -27.2% |
净利率OFIXXPER
| Q4 25 | -1.0% | -14.7% | ||
| Q3 25 | -11.1% | -5.5% | ||
| Q2 25 | -6.9% | -14.0% | ||
| Q1 25 | -27.4% | -16.1% | ||
| Q4 24 | -13.5% | 37.8% | ||
| Q3 24 | -13.9% | -12.6% | ||
| Q2 24 | -16.8% | -25.3% | ||
| Q1 24 | -19.1% | -11.0% |
每股收益（稀释后）OFIXXPER
| Q4 25 | $-0.05 | $-0.37 | ||
| Q3 25 | $-0.57 | $-0.13 | ||
| Q2 25 | $-0.36 | $-0.32 | ||
| Q1 25 | $-1.35 | $-0.41 | ||
| Q4 24 | $-0.76 | $1.02 | ||
| Q3 24 | $-0.71 | $-0.37 | ||
| Q2 24 | $-0.88 | $-0.67 | ||
| Q1 24 | $-0.95 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $96.8M |
| 总债务越低越好 | — | $27.7M |
| 股东权益账面价值 | $450.0M | $414.1M |
| 总资产 | $850.6M | $615.8M |
| 负债/权益比越低杠杆越低 | — | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资OFIXXPER
| Q4 25 | $82.0M | $96.8M | ||
| Q3 25 | $62.9M | $96.8M | ||
| Q2 25 | $65.6M | $95.1M | ||
| Q1 25 | $58.0M | $88.0M | ||
| Q4 24 | $83.2M | $130.6M | ||
| Q3 24 | $30.1M | $72.7M | ||
| Q2 24 | $26.4M | $92.5M | ||
| Q1 24 | $27.0M | $95.2M |
总债务OFIXXPER
| Q4 25 | — | $27.7M | ||
| Q3 25 | $157.2M | $27.7M | ||
| Q2 25 | $157.0M | $27.7M | ||
| Q1 25 | $156.9M | $27.7M | ||
| Q4 24 | $157.0M | $27.7M | ||
| Q3 24 | $118.5M | $27.7M | ||
| Q2 24 | $118.0M | $27.7M | ||
| Q1 24 | $118.2M | $27.7M |
股东权益OFIXXPER
| Q4 25 | $450.0M | $414.1M | ||
| Q3 25 | $442.5M | $421.0M | ||
| Q2 25 | $458.3M | $419.8M | ||
| Q1 25 | $458.3M | $418.9M | ||
| Q4 24 | $503.1M | $429.1M | ||
| Q3 24 | $525.9M | $377.4M | ||
| Q2 24 | $546.0M | $388.7M | ||
| Q1 24 | $570.3M | $399.1M |
总资产OFIXXPER
| Q4 25 | $850.6M | $615.8M | ||
| Q3 25 | $832.6M | $628.8M | ||
| Q2 25 | $837.2M | $629.2M | ||
| Q1 25 | $823.1M | $633.5M | ||
| Q4 24 | $893.3M | $667.8M | ||
| Q3 24 | $867.9M | $616.2M | ||
| Q2 24 | $882.0M | $619.2M | ||
| Q1 24 | $906.0M | $630.4M |
负债/权益比OFIXXPER
| Q4 25 | — | 0.07× | ||
| Q3 25 | 0.36× | 0.07× | ||
| Q2 25 | 0.34× | 0.07× | ||
| Q1 25 | 0.34× | 0.07× | ||
| Q4 24 | 0.31× | 0.06× | ||
| Q3 24 | 0.23× | 0.07× | ||
| Q2 24 | 0.22× | 0.07× | ||
| Q1 24 | 0.21× | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $4.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $1.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 1.0% |
| 资本支出强度资本支出/营收 | 4.9% | 2.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-5.9M |
8季度趋势，按日历期对齐
经营现金流OFIXXPER
| Q4 25 | $27.7M | $4.1M | ||
| Q3 25 | $12.4M | $7.5M | ||
| Q2 25 | $11.6M | $10.1M | ||
| Q1 25 | $-18.4M | $-22.3M | ||
| Q4 24 | $23.7M | $1.2M | ||
| Q3 24 | $11.7M | $-4.6M | ||
| Q2 24 | $9.0M | $-2.1M | ||
| Q1 24 | $-18.6M | $-49.8M |
自由现金流OFIXXPER
| Q4 25 | $16.8M | $1.2M | ||
| Q3 25 | $2.5M | $6.7M | ||
| Q2 25 | $4.5M | $9.5M | ||
| Q1 25 | $-25.1M | $-23.3M | ||
| Q4 24 | $15.2M | $-510.0K | ||
| Q3 24 | $6.3M | $-5.6M | ||
| Q2 24 | $-360.0K | $-2.6M | ||
| Q1 24 | $-29.1M | $-51.6M |
自由现金流率OFIXXPER
| Q4 25 | 7.6% | 1.0% | ||
| Q3 25 | 1.2% | 6.0% | ||
| Q2 25 | 2.2% | 9.0% | ||
| Q1 25 | -13.0% | -20.5% | ||
| Q4 24 | 7.0% | -0.4% | ||
| Q3 24 | 3.2% | -4.2% | ||
| Q2 24 | -0.2% | -2.2% | ||
| Q1 24 | -15.4% | -43.4% |
资本支出强度OFIXXPER
| Q4 25 | 4.9% | 2.5% | ||
| Q3 25 | 4.8% | 0.7% | ||
| Q2 25 | 3.5% | 0.5% | ||
| Q1 25 | 3.5% | 0.9% | ||
| Q4 24 | 4.0% | 1.4% | ||
| Q3 24 | 2.7% | 0.8% | ||
| Q2 24 | 4.7% | 0.4% | ||
| Q1 24 | 5.6% | 1.6% |
现金转化率OFIXXPER
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
XPER
| Pay TV | $56.2M | 48% |
| Connected Car | $31.3M | 27% |
| Consumer Electronics | $17.2M | 15% |
| Media Platform | $11.8M | 10% |
